[Biological therapy as treatment of inflammatory bowel diseases].
Biological therapy as treatment of inflammatory bowel diseases has been one of the major achievements since the introduction of steroids. Infliximab has been approved for the treatment of Crohn's disease and ulcerative colitis, and adalimumab for the treatment of Crohn's disease. Both treatments have documented effect for induction of clinical response and remission, and can be used to maintain remission. However, it is important to define the treatment goals before initiation, and whether biologicals should be used alone or together with immunosuppressants as azathioprine.
Agnholt
Jørgen
J
Arhus Universitetshospital, Arhus Sygehus, Medicinsk Hepato-gastroenterologisk Afdeling V, Arhus C. jorge@as.aaa.dk
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069285:Infliximab; D000068879:Adalimumab; D001379:Azathioprine; D008727:Methotrexate